Concomitant toxicokinetics is the acquisition of pharmacokinetic data within a non-clinical toxicity study or in a supportive study designed for that purpose. It determines the systemic exposure of test animals and contrasts it with toxicological findings. Its objective is not the complete description of drug kinetics, but rather the robust interpretation of safety findings for clinical development.<\/p>\n
An administered dose does not reliably indicate the actual amount of active substance reaching the organism. Absorption, distribution, metabolism, and elimination can change with dose, species, sex, or duration of treatment. Toxicokinetic measurements therefore record exposure and can demonstrate whether a finding is related to concentration, repeated administration, or saturation of elimination.<\/p>\n
ICH S3A defines toxicokinetics as the generation of pharmacokinetic data as an integral part of non-clinical toxicity studies or in specially designed supportive studies to assess systemic exposure. The data are intended to help interpret toxicological results and their relevance to clinical safety issues. The guideline does not require a rigid scheme, but rather a case-by-case decision on the scope and timing of measurements.<\/p>\n
Sampling must reflect the objectives of the toxicity study. In the case of repeated administration, changes in exposure over time, dose-level dependence, or high concentrations at exposure limits may be significant. For a usable comparison, animal numbers, time points, dosage, sample matrix, and analytical methods are clearly linked to pathological and clinical-chemical findings.<\/p>\n
Bioanalytical procedures for non-clinical TK studies fall within the scope of ICH M10 if they are conducted according to GLP principles. Method validation demonstrates that a measurement is fit for its purpose; however, it does not replace toxicokinetic interpretation. Only the combination of concentration data with toxicity findings answers the question of which systemic burden can be assigned to a safety risk.<\/p>\n
Pharmacokinetics generally describes the time course of an active substance in the body and the associated parameters. Concomitant toxicokinetics uses such data for a narrower task: it is intended to explain non-clinical toxicity findings in light of the exposure achieved. The focus is thus on safety interpretation, rather than the most complete characterization possible of a candidate’s kinetic properties.<\/p>\n
Toxicokinetics also fulfills a different role compared to the No Observed Adverse Effect Level. The NOAEL identifies a dose level without adverse findings; TK data can clarify what exposure existed at this level and how it is to be categorized between species. The existing entries for pharmacokinetics and pharmacokinetics concern the umbrella term, while this page describes the toxicological application.<\/p>\n
TK data also help to identify differences between low, medium, and high dose levels. If exposure increases disproportionately, a small nominal dose increase can lead to a significantly higher systemic burden. Conversely, limited absorption or induced elimination can explain why a higher administered dose generates little additional exposure. Such patterns change the significance of dose-response relationships in toxicology.<\/p>\n
Metabolites deserve special attention if they occur to different extents in animals or humans. Toxicokinetic assessment can show whether a finding is attributable to the parent compound, a metabolite, or a combination of exposures. It thus also supports the decision as to whether additional metabolite-specific analyses are required for clinical safety assessment.<\/p>\n
Reporting should transparently present the relationship between dose, measured concentration, and toxicological observation. If samples are only collected from individual dose groups or at specific time points for methodological reasons, this limitation must also be disclosed for subsequent clinical extrapolation.<\/p>\n
When preparing for the first-in-human study, TK results provide the bridge between animal dose data and expected human exposure. They help plan dose escalations based not just on nominal doses, but on safety margins. If animal findings only occur with disproportionately increasing exposure, this characteristic must be incorporated into clinical monitoring and the justification of the maximum exposure range.<\/p>\n
Full-service CROs like Mediconomics support the TK strategy by coordinating sampling plans, bioanalytical requirements, and the integration of exposure and toxicology data. Non-clinical consulting, biostatistics, and medical writing can use this to create tables and narratives for the Investigator\u2019s Brochure, study protocol, and regulatory documents.<\/p>\n
Does every toxicity study have to include toxicokinetic measurements?<\/strong><\/p>\n There is no universal TK requirement. ICH S3A recommends a scientific case-by-case decision on when and to what extent exposure data are useful for risk assessment.<\/p>\n Why can identical doses yield different TK results?<\/strong><\/p>\n Systemic exposure can deviate due to species differences, dose dependency, or changes during repeated application.<\/p>\n What is the connection between TK and the starting dose?<\/strong><\/p>\n The exposure measured in animals facilitates comparison with expected human exposure and thus the justification of a cautious clinical dose.<\/p>\n Concomitant toxicokinetics is the acquisition of pharmacokinetic data within a non-clinical toxicity study or in a supportive study designed for that purpose. It determines the systemic exposure of test animals and contrasts it with toxicological findings. Its objective is not the complete description of drug kinetics, but rather the robust interpretation of safety findings for […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[27],"class_list":["post-8016","glossary","type-glossary","status-publish","hentry","glossary-cat-nichtklinik-pharmakologie"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8016\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8016"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n